Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Net Cash Flow (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Net Cash Flow for 12 consecutive years, with -$15.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow fell 32.25% year-over-year to -$15.2 million, compared with a TTM value of -$54.8 million through Sep 2025, down 176.35%, and an annual FY2024 reading of $127.1 million, up 2303.24% over the prior year.
  • Net Cash Flow was -$15.2 million for Q3 2025 at Avalo Therapeutics, up from -$82.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $102.8 million in Q1 2024 and bottomed at -$82.7 million in Q2 2025.
  • Average Net Cash Flow over 5 years is $429947.4, with a median of -$3.9 million recorded in 2022.
  • The sharpest move saw Net Cash Flow crashed 1444.51% in 2022, then soared 2784.25% in 2024.
  • Year by year, Net Cash Flow stood at -$17.0 million in 2021, then soared by 77.35% to -$3.9 million in 2022, then increased by 28.33% to -$2.8 million in 2023, then skyrocketed by 2004.7% to $52.7 million in 2024, then crashed by 128.95% to -$15.2 million in 2025.
  • Business Quant data shows Net Cash Flow for AVTX at -$15.2 million in Q3 2025, -$82.7 million in Q2 2025, and -$9.5 million in Q1 2025.